Pharmaceutical Payments to Certified Oncology Specialists in Japan in 2016: a Retrospective Observational Cross-sectional Analysis

Overview

Journal BMJ Open

Specialty General Medicine

Date 2019 Sep 9

PMID 31494604

Citations 21

Authors

Akihiko Ozaki

Hiroaki Saito

Yosuke Onoue

Toyoaki Sawano

Yuki Shimada

Yurie Somekawa

Aritsune Tsuji

Tetsuya Tanimoto

Affiliations

Soon will be listed here.

Abstract

Objective: This study investigated payments made by pharmaceutical companies to oncology specialists in Japan, what the payments were for and whether the receipt of such payments contravened any conflict of interest (COI) regulations.

Design, Setting And Participants: Payment data to physicians, as reported by all pharmaceutical companies belonging to the Japan Pharmaceutical Manufacturers Association, were retrospectively extracted for 2016. Of the named individual recipients of payments, all certified oncologists were identified, using certification data from the Japanese Society of Medical Oncology (JSMO). The individual specialisations of each of the oncologists was also identified.

Outcome: Payments to individual cancer specialists and what they were for were identified. Factors associated with receipt of higher value payments and payment flows to specialties were determined. Companies selling oncology drugs with annual sales of ≥5 billion yen (£33.9 million, €40.2 million and $46.0 million) (high revenue-generating drugs) were identified.

Results: In total, 59 companies made at least one payment to oncologists. Of the 1080 oncology specialists identified, 763 (70.6%) received at least one payment, while 317 received no payment. Of the 763, some 142 (13.1%) receiving at least 1 million yen (£6,800, €8,000 and $9200) accounted for 71.5% of the total. After adjustment of covariates, working for university hospitals and cancer hospitals and male gender were key factors associated with larger monetary payments. Payments preferentially targeted on cancer specialties using high revenue-generating drugs. The JSMO has its own COI policy for its members, but the policy did not mention any specific guidelines for certified oncology specialists.

Conclusion: Financial relationships were identified and quantified between pharmaceutical companies and oncology specialists, but the extent and worth varied significantly. Given the frequency and amounts of money involved in such linkages, it would be beneficial for specific COI regulations to be developed and policed for oncologists.

Citing Articles

Increasing trends of pharmaceutical payments to breast cancer specialists in Japan: A retrospective study from 2016 to 2019.

Kaneda Y, Yamashita E, Saito H, Gonda K, Wada M, Tanimoto T PLoS One. 2024; 19(9):e0310880.

PMID: 39325782 PMC: 11426427. DOI: 10.1371/journal.pone.0310880.

An analysis of research grants allocated to researchers by the Smoking Research Foundation funded by Japan Tobacco Inc. in 2018.

Shiga R, Nakagawasai S, Hashimoto E, Cho I, Saito H, Ozaki A Tob Prev Cessat. 2024; 10.

PMID: 39070754 PMC: 11274627. DOI: 10.18332/tpc/191140.

Nature and Trend of Pharmaceutical Payments to Japanese Board-Certified Neurologists Between 2016 and 2019: A Pre-emergence Analysis Amidst the Development of Next-Generation Alzheimer's Disease Drugs.

Shrestha R, Saito H, Yamashita E, Shrestha S, Tanimoto T, Ozaki A Cureus. 2024; 16(2):e53848.

PMID: 38465045 PMC: 10924646. DOI: 10.7759/cureus.53848.

Association between Conflicts of Interest Disclosure and Quality of Clinical Practice Guidelines in Japan: A Meta-Epidemiological Study.

Yamamoto N, Ozaki A, Taito S, Ariie T, Someko H, Saito H J Pers Med. 2023; 13(12).

PMID: 38138949 PMC: 10744963. DOI: 10.3390/jpm13121722.

Assessment of Financial Relationships Between Otorhinolaryngologists and Pharmaceutical Companies in Japan Between 2016 and 2019.

Kamamoto S, Ozaki A, Murayama A Cureus. 2023; 15(8):e43633.

PMID: 37719565 PMC: 10503947. DOI: 10.7759/cureus.43633.

References

Mulinari S, Ozieranski P . Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry's Disclosure UK database, 2015 and 2016 cohorts. BMJ Open. 2018; 8(10):e023094. PMC: 6196800. DOI: 10.1136/bmjopen-2018-023094. View

Saito H, Ozaki A, Sawano T, Shimada Y, Tanimoto T . Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan. JAMA Netw Open. 2019; 2(4):e192834. PMC: 6487566. DOI: 10.1001/jamanetworkopen.2019.2834. View

DeJong C, Aguilar T, Tseng C, Lin G, Boscardin W, Dudley R . Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries. JAMA Intern Med. 2016; 176(8):1114-1122. DOI: 10.1001/jamainternmed.2016.2765. View

Saito H, Ozaki A, Kobayashi Y, Sawano T, Tanimoto T . Pharmaceutical Company Payments to Executive Board Members of Professional Medical Associations in Japan. JAMA Intern Med. 2019; 179(4):578-580. PMC: 6450293. DOI: 10.1001/jamainternmed.2018.7283. View

Agrawal S, Brown D . The Physician Payments Sunshine Act--Two Years of the Open Payments Program. N Engl J Med. 2016; 374(10):906-9. DOI: 10.1056/NEJMp1509103. View

Tanimoto T, Kami M, Shibuya K . Misconduct: Japan to learn from biomedical cases. Nature. 2014; 512(7515):371. DOI: 10.1038/512371d. View

Light D, Kantarjian H . Market spiral pricing of cancer drugs. Cancer. 2013; 119(22):3900-2. DOI: 10.1002/cncr.28321. View

Narumi H, Takano H, Shindo S, Fujita M, Mizuma H, Kuwabara Y . Retraction: Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial. Hypertens Res. 2016; 40(1):103. DOI: 10.1038/hr.2016.144. View

Kobashi Y, Watanabe M, Kimura H, Higuchi A, Ozaki A . Are Pharmaceutical Company Payments Incentivising Malpractice in Japanese Physicians?. Int J Health Policy Manag. 2019; 8(10):627-628. PMC: 6819628. DOI: 10.15171/ijhpm.2019.60. View

10.

Kantarjian H, Rajkumar S . Why are cancer drugs so expensive in the United States, and what are the solutions?. Mayo Clin Proc. 2015; 90(4):500-4. DOI: 10.1016/j.mayocp.2015.01.014. View

11.

Tibi-Levy Y, de Pouvourville G, Westerloppe J, Bamberger M . The cost of treating high blood pressure in general practice in France. Eur J Health Econ. 2007; 9(3):229-36. DOI: 10.1007/s10198-007-0065-2. View

12.

Ismaila N, Salako O, Mutiu J, Adebayo O . Oncology Guidelines Usage in a Low- and Middle-Income Country. J Glob Oncol. 2018; 4:1-6. PMC: 6223435. DOI: 10.1200/JGO.17.00136. View

13.

Tringale K, Marshall D, Mackey T, Connor M, Murphy J, Hattangadi-Gluth J . Types and Distribution of Payments From Industry to Physicians in 2015. JAMA. 2017; 317(17):1774-1784. PMC: 5470350. DOI: 10.1001/jama.2017.3091. View

14.

. Retraction--Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2013; 382(9895):843. DOI: 10.1016/S0140-6736(13)61847-4. View

15.

Fitzmaurice C, Akinyemiju T, Al Lami F, Alam T, Alizadeh-Navaei R, Allen C . Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2018; 4(11):1553-1568. PMC: 6248091. DOI: 10.1001/jamaoncol.2018.2706. View

16.

Mitchell A, Basch E, Dusetzina S . Financial Relationships With Industry Among National Comprehensive Cancer Network Guideline Authors. JAMA Oncol. 2016; 2(12):1628-1631. DOI: 10.1001/jamaoncol.2016.2710. View

17.

Zafar S, Peppercorn J, Schrag D, Taylor D, Goetzinger A, Zhong X . The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist. 2013; 18(4):381-90. PMC: 3639525. DOI: 10.1634/theoncologist.2012-0279. View

18.

Zhuo X, Zhang P, Kahn H, Bardenheier B, Li R, Gregg E . Change in medical spending attributable to diabetes: national data from 1987 to 2011. Diabetes Care. 2015; 38(4):581-7. DOI: 10.2337/dc14-1687. View

19.

Agrawal S, Brennan N, Budetti P . The Sunshine Act--effects on physicians. N Engl J Med. 2013; 368(22):2054-7. DOI: 10.1056/NEJMp1303523. View

20.

Ozaki A . Conflict of Interest and the CREATE-X Trial in the New England Journal of Medicine. Sci Eng Ethics. 2017; 24(6):1809-1811. DOI: 10.1007/s11948-017-9966-3. View